MX2012003519A - Formulaciones que comprenden compuestos de triptano. - Google Patents

Formulaciones que comprenden compuestos de triptano.

Info

Publication number
MX2012003519A
MX2012003519A MX2012003519A MX2012003519A MX2012003519A MX 2012003519 A MX2012003519 A MX 2012003519A MX 2012003519 A MX2012003519 A MX 2012003519A MX 2012003519 A MX2012003519 A MX 2012003519A MX 2012003519 A MX2012003519 A MX 2012003519A
Authority
MX
Mexico
Prior art keywords
administration
provides
triptan
contemplated
aspects
Prior art date
Application number
MX2012003519A
Other languages
English (en)
Other versions
MX338110B (es
Inventor
Rajesh Gandhi
Sreekanth Manikonda
Arun Jana
Sameer Shrinivas Kunte
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Publication of MX2012003519A publication Critical patent/MX2012003519A/es
Publication of MX338110B publication Critical patent/MX338110B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona una composición farmacéutica para administración intranasal que comprende una sal de sumatriptano o un solvato fisiológicamente aceptable de la misma, un alquil glicósido o éster de alquil sacárido y opcionalmente al menos un excipiente farmacéuticamente aceptable, en donde la composición proporciona un valor Tmax de menos de 30 minutos en la administración. Se contemplan y describen otros aspectos y modalidades. La invención también proporciona una composición farmacéutica para administración intranasal que comprende un triptano, un vehículo farmacéuticamente aceptable y un potenciador de permeación de la mucosa, en donde en la administración la composición proporciona un Tmax sustancialmente equivalente a administración subcutánea del triptano. Otros aspectos y modalidades se contemplan y describen.
MX2012003519A 2009-09-25 2010-06-17 Formulaciones que comprenden compuestos de triptano. MX338110B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN2337CH2009 2009-09-25
IN2607CH2009 2009-10-27
US29221310P 2010-01-05 2010-01-05
US29220610P 2010-01-05 2010-01-05
US81690410A 2010-06-16 2010-06-16
USPCT/US10/38838 2010-06-16
PCT/IB2010/001708 WO2011036521A2 (en) 2009-09-25 2010-06-17 Formulations comprising triptan compounds

Publications (2)

Publication Number Publication Date
MX2012003519A true MX2012003519A (es) 2012-04-19
MX338110B MX338110B (es) 2016-04-01

Family

ID=43742393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003519A MX338110B (es) 2009-09-25 2010-06-17 Formulaciones que comprenden compuestos de triptano.

Country Status (10)

Country Link
US (5) US9211282B2 (es)
EP (1) EP2480197B1 (es)
KR (1) KR101646079B1 (es)
AU (1) AU2010299607B2 (es)
CA (1) CA2775404C (es)
DK (1) DK2480197T3 (es)
MX (1) MX338110B (es)
NZ (1) NZ599344A (es)
RU (2) RU2012116452A (es)
WO (1) WO2011036521A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
CA2775404C (en) 2009-09-25 2017-01-03 Dr. Reddy's Laboratories Limited Formulations comprising triptan compounds
US11324746B2 (en) 2014-12-22 2022-05-10 Arovella Therapeutics Limited Use of anagrelide for treating cancer
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
IL266537B2 (en) * 2016-11-15 2023-12-01 Klaria Pharma Holding Ab pharmaceutical preparation
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
US20220096438A1 (en) * 2018-09-07 2022-03-31 Upsher-Smith Laboratories, Llc Methods of treating migraine
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
WO2021122793A1 (en) * 2019-12-17 2021-06-24 Norinvent Ab Sulfated disaccharides as enhancers of transmucosal drug uptake
RS63725B1 (sr) 2020-05-18 2022-12-30 Orexo Ab Nova farmaceutska kompozicija za davanje leka
WO2023014978A2 (en) * 2021-08-06 2023-02-09 Rebalance Health, Inc. Growth hormone-releasing hormone peptides and formulations thereof
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79215B (es) 1982-06-07 1984-10-22 Glaxo Group Ltd
GB8332435D0 (en) 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
IT8422764V0 (it) 1984-07-31 1984-07-31 Rockwell Rimoldi Spa Crochet inferiore di macchina per cucire atta a formare il punto sopraggitto.
GB2162522B (en) 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
US5270333A (en) * 1986-01-28 1993-12-14 Glaxo Group Limited Indole derivatives
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
GB9026998D0 (en) * 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
GB9102579D0 (en) 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
GB9125699D0 (en) 1991-12-03 1992-01-29 Glaxo Group Ltd Device
DE4314976C1 (de) 1993-05-06 1994-10-06 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
JP2000505090A (ja) 1996-07-11 2000-04-25 ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ インドール選択的セロトニンアゴニストを含む包接錯体
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001039836A1 (en) 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
US20030013753A1 (en) 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
ATE424186T1 (de) * 2001-12-21 2009-03-15 3M Innovative Properties Co Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff
US7497214B2 (en) * 2002-09-16 2009-03-03 3M Innovative Properties Company Aerosol dispensers and adaptors therefor
WO2004093917A2 (en) * 2003-04-22 2004-11-04 Nastech Pharmaceutical Company Inc. Intranasal administration of triptans
US7459146B2 (en) 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US20090047347A1 (en) 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20060046969A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
EP2457580A1 (en) 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
EP1863511A2 (en) 2005-02-23 2007-12-12 UAB Research Foundation Alkyl-glycoside enhanced vaccination
US20090136505A1 (en) * 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
EP1998832B1 (en) 2006-03-24 2014-10-22 3M Innovative Properties Company Method for assessing the suitability of metered dose inhaler actuators
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
EP2162522B1 (en) * 2007-06-22 2018-07-04 Unilever N.V. Granular enzymatic detergent compositions
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
US8440631B2 (en) * 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
CA2775404C (en) 2009-09-25 2017-01-03 Dr. Reddy's Laboratories Limited Formulations comprising triptan compounds
JP5776355B2 (ja) * 2010-07-16 2015-09-09 大正製薬株式会社 内服液剤

Also Published As

Publication number Publication date
US20110077281A1 (en) 2011-03-31
NZ599344A (en) 2015-02-27
US10603305B2 (en) 2020-03-31
KR20120089853A (ko) 2012-08-14
AU2010299607A1 (en) 2012-04-12
US9974770B2 (en) 2018-05-22
RU2019142130A3 (es) 2021-06-18
EP2480197B1 (en) 2015-11-11
MX338110B (es) 2016-04-01
KR101646079B1 (ko) 2016-08-12
AU2010299607A2 (en) 2012-04-26
EP2480197A2 (en) 2012-08-01
US9211282B2 (en) 2015-12-15
US20180207130A1 (en) 2018-07-26
CA2775404A1 (en) 2011-03-31
RU2762725C2 (ru) 2021-12-22
DK2480197T3 (en) 2016-01-25
WO2011036521A3 (en) 2011-05-26
CA2775404C (en) 2017-01-03
RU2012116452A (ru) 2013-10-27
US20160045474A1 (en) 2016-02-18
RU2019142130A (ru) 2021-06-18
WO2011036521A2 (en) 2011-03-31
AU2010299607B2 (en) 2016-07-28
US9610280B2 (en) 2017-04-04
US20170157091A1 (en) 2017-06-08
US20230025210A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
MX2012003519A (es) Formulaciones que comprenden compuestos de triptano.
WO2005046575A3 (en) Amino acid prodrugs
PH12014501082B1 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012054500A3 (en) Compositions for drug administration
MX2009002666A (es) Compuestos de n-metilaminometil isoindol, composiciones que los comprenden y metodos que utilizan los mismos.
MY175079A (en) Sweet flavor modifier
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
MX342613B (es) Geles con base de acido hialuronico que incluyen agentes anestesicos.
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
IL197574A0 (en) Pharmaceutical compositions
AP2714A (en) Orodispersible pharmaceutical composition for or omucosal or sublingual administration of agomelati ne
WO2008094910A3 (en) Hyaluronate compositions
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
ZA200800239B (en) Mucosal or enteral administration of biobogically active macromolecules
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
WO2010132765A3 (en) Antibacterial aminoglycoside analogs
MX2011005633A (es) Formas de dosificacion solida de bendamustina.
MX2010004211A (es) Composicion oftalmica que comprende una prostaglandina.
EA200601901A1 (ru) Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием
TNSN08369A1 (en) Benzimidazole derivatives
WO2006079077A3 (en) Use of diltiazem or analogs thereof as modulators of ghrelin receptor
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions

Legal Events

Date Code Title Description
FG Grant or registration